Esmolol as a cardioprotective agent to reduce low cardiac output syndrome after cardiac surgery

Early postoperative left ventricular dysfunction due to myocardial stunning can negatively affect outcomes in patients with mitral regurgitation undergoing mitral valve surgery. The aim of this study was to evaluate the impact of the ultra-short acting β-blocking agent esmolol, administered after the anesthesia induction and before aortic cross-clamping, on myocardial protection and on postoperative clinical course in patients undergoing mitral valve surgery for mitral regurgitation. Patients undergoing mitral valve surgery for primary mitral regurgitation were analyzed according to the use or not of esmolol. Clinical, procedural and laboratory data were collected. A 1:2 propensity score matching analysis (esmolol vs. control) was performed to adjust for baseline differences. The primary endpoint was the occurrence of postoperative low cardiac output syndrome. Out of 322 patients (age: 66 ± 11 years; 140 women) with mitral regurgitation undergoing mitral valve surgery, 99 received esmolol while 223 patients did not. Low cardiac output syndrome occurred significantly less frequently in patients treated with esmolol as compared to patients not receiving it (12.1% vs. 33.2%, p < 0.001 before matching and 13.0% vs. 30.4%, p = 0.006 after matching). Peak post-procedural creatin kinase MB release was lower in patients treated with esmolol as compared to those not treated with esmolol (57 ± 30 µg/mL vs. 82 ± 70 µg/mL, p < 0.001 before matching and 57 ± 31 µg/mL vs. 83 ± 79 µg/mL, p = 0.008 after matching). Acute kidney injury and length of intensive care unit stay were reduced in the esmolol group both before and after matching. In conclusion esmolol administered after anesthesia induction and before aortic cross-clamping could improve myocardial protection in patients with mitral regurgitation undergoing mitral valve surgery.

Anesthesia; Esmolol; β-blockers; Cardiac surgery; Mitral valve surgery; Low cardiac output syndrome; Intensive care

[1] Badhwar V, Vemulapalli S, Mack MA, Gillinov AM, Chikwe J, Dearani JA, et al. Volume-outcome association of mitral valve surgery in the United States. JAMA Cardiology. 2020; 5: 1092–1101.

[2] Joung KW, Kim SO, Nam JS, Moon YJ, Bae HJ, Chin JH, et al. Changes in left ventricular ejection fraction after mitral valve repair for primary mitral regurgitation. Journal of Clinical Medicine. 2021; 10: 2830.

[3] Althunayyan AM, Alborikan S, Badiani S, Wong K, Uppal R, Patel N, et al. Determinants of post-operative left ventricular dysfunction in degenerative mitral regurgitation. European Heart Journal—Cardiovascular Imaging. 2023; 24: 1252–1257.

[4] Kislitsina ON, Thomas JD, Crawford E, Michel E, Kruse J, Liu M, et al. Predictors of left ventricular dysfunction after surgery for degenerative mitral regurgitation. The Annals of Thoracic Surgery. 2020; 109: 669–677.

[5] Quintana E, Suri RM, Thalji NM, Daly RC, Dearani JA, Burkhart HM, et al. Left ventricular dysfunction after mitral valve repair—the fallacy of “normal” preoperative myocardial function. The Journal of Thoracic and Cardiovascular Surgery. 2014; 148: 2752–2760.

[6] Rana KB, Ansari A, Sharma P, Yadav L, Shahbaz A. Frequency of low cardiac output syndrome following on pump coronary artery bypass grafting surgery and it’s association with degree of pre-operative left ventricular dysfunction. Kathmandu University Medical Journal. 2023; 21: 79–84.

[7] Ng Yin Ling C, Avci Demir F, Bleetman D, Eskandari M, Khan H, Baghai M, et al. The impact of complete versus partial preservation of the sub-valvular apparatus on left ventricular function in mitral valve replacement. Journal of Cardiac Surgery. 2022; 37: 4598–4605.

[8] Lee R, Marwick TH. Assessment of subclinical left ventricular dysfunction in asymptomatic mitral regurgitation. European Journal of Echocardiography. 2007; 8: 175–184.

[9] Levitsky S. Protecting the myocardial cell during coronary revascularization. Circulation. 2006; 114: I339–I343.

[10] Ferrari R, Balla C, Malagù M, Guardigli G, Morciano G, Bertini M, et al. Reperfusion damage—a story of success, failure, and hope. Circulation Journal. 2017; 81: 131–141.

[11] Nakamura Y, Saito S, Miyagawa S, Yoshikawa Y, Hata H, Yoshioka D, et al. Perioperative ischaemic reperfusion injury and allograft function in the early post-transplantation period. Interdisciplinary CardioVascular and Thoracic Surgery. 2019; 29: 230–236.

[12] Kim H, Shin YC. Temporary use of unusually high dose of catecholamine improved severe ventricular dysfunction associated with stunned myocardium without significant myocardial injury in a post cardiac surgical patient: a case report. International Journal of Surgery Case Reports. 2020; 76: 282–284.

[13] Zangrillo A, Bignami E, Noè B, Nardelli P, Licheri M, Gerli C, et al. Esmolol in cardiac surgery: a randomized controlled trial. Journal of Cardiothoracic and Vascular Anesthesia. 2021; 35: 1106–1114.

[14] Bignami E, Guarnieri M, Franco A, Gerli C, De Luca M, Monaco F, et al. Esmolol before cardioplegia and as cardioplegia adjuvant reduces cardiac troponin release after cardiac surgery. A randomized trial. Perfusion. 2017; 32: 313–320.

[15] Kinoshita M, Butt AL, Kinoshita H, Tanaka KA. Does selective β1 blockade with landiolol improve mortality after coronary artery bypass graft surgery? Anesthesia and Analgesia. 2024; 138: e17–e18.

[16] Devereaux PJ, Lamy A, Chan MTV, Allard RV, Lomivorotov VV, Landoni G, et al. High-sensitivity troponin i after cardiac surgery and 30-day mortality. The New England Journal of Medicine. 2022; 386: 827–836.

[17] Zangrillo A, Turi S, Crescenzi G, Oriani A, Distaso F, Monaco F, et al. Esmolol reduces perioperative ischemia in cardiac surgery: a meta-analysis of randomized controlled studies. Journal of Cardiothoracic and Vascular Anesthesia. 2009; 23: 625–632.

[18] Wiest DB, Haney JS. Clinical pharmacokinetics and therapeutic efficacy of esmolol. Clinical Pharmacokinetics. 2012; 51: 347–356.

[19] Thiele H, Zeymer U, Neumann F, Ferenc M, Olbrich H, Hausleiter J, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. The New England Journal of Medicine. 2012; 367: 1287–1296.

[20] Crescenzi G, Torracca L, Pierri MD, Rosica C, Munch C, Capestro F. ‘Early’ and ‘late’ timing for renal replacement therapy in acute kidney injury after cardiac surgery: a prospective, interventional, controlled, single-centre trial. Interactive CardioVascular and Thoracic Surgery. 2015; 20: 616–621.

[21] Lapenna E, Torracca L, De Bonis M, La Canna G, Crescenzi G, Alfieri O. Minimally invasive mitral valve repair in the context of barlow’s disease. The Annals of Thoracic Surgery. 2005; 79: 1496–1499.

[22] Torracca L, Lapenna E, De Bonis M, Kassem S, La Canna G, Crescenzi G, et al. Minimally invasive mitral valve repair as a routine approach in selected patients. Journal of Cardiovascular Medicine. 2006; 7: 57–60.

[23] Vinsant C, Holecko J, Whitson B, Turner K. Aggressive treatment of afterload mismatch to address left ventricular dysfunction after mitral valve repair: a case report. International Journal of Critical Illness and Injury Science. 2020; 10: 148–151.

[24] Perl L, Kheifets M, Guido A, Agricola E, Denti P, Wild MG, et al. Acute reduction in left ventricular function following transcatheter mitral edge-to-edge repair. Journal of the American Heart Association. 2023; 12: e029735.

[25] Ueyama H, Kuno T, Takagi H, Krishnamoorthy P, Prandi FR, Palazzuoli A, et al. Prognostic value of left ventricular global longitudinal strain in mitral regurgitation: a systematic review. Heart Failure Reviews. 2023; 28: 465–483.

[26] Jogani S, Van de Heyning CM, Paelinck BP, De Bock D, Mertens P, Heidbuchel H, et al. Afterload mismatch after mitraclip implantation: intraoperative assessment and prognostic implications. The Journal of Invasive Cardiology. 2020; 32: 88–93.

[27] Rothenburger M, Rukosujew A, Hammel D, Dorenkamp A, Schmidt C, Schmid C, et al. Mitral valve surgery in patients with poor left ventricular function. The Thoracic and Cardiovascular Surgeon. 2002; 50: 351–354.

[28] Buckberg GD, Athanasuleas CL. Left ventricular dysfunction after mitral valve repair: predetermined or caused? The Journal of Thoracic and Cardiovascular Surgery. 2015; 149: 940.

[29] Crescenzi G, Capestro F, Torracca L. Left ventricular function after mitral surgery: time to focus on intraoperative management? The Journal of Thoracic and Cardiovascular Surgery. 2015; 150: 741.

[30] Crescenzi G, Bove T, Pappalardo F, Scandroglio AM, Landoni G, Aletti G, et al. Clinical significance of a new Q wave after cardiac surgery. European Journal of Cardio—Thoracic Surgery. 2004; 25: 1001–1005.

[31] Er F, Dahlem KM, Nia AM, Erdmann E, Waltenberger J, Hellmich M, et al. Randomized control of sympathetic drive with continuous intravenous esmolol in patients with acute ST-segment elevation myocardial infarction. JACC: Cardiovascular Interventions. 2016; 9: 231–240.

[32] Iwasaki Y, Ohbe H, Nakajima M, Sasabuchi Y, Ikumi S, Kaiho Y, et al. Association between intraoperative landiolol use and in-hospital mortality after coronary artery bypass grafting: a nationwide observational study in Japan. Anesthesia & Analgesia. 2023; 137: 1208–1215.

[33] Poveda-Jaramillo R, Monaco F, Zangrillo A, Landoni G. Ultra-short-acting β-blockers (esmolol and landiolol) in the perioperative period and in critically Ill patients. Journal of Cardiothoracic and Vascular Anesthesia. 2018; 32: 1415–1425.

[34] Zhu D, Li Y, Tian AY, Wang HN. Comparison of amiodarone and esmolol for prevention of reperfusion ventricular fibrillation in individuals undergoing heart valve or aortic surgery: a study protocol for a randomized controlled clinical trial. Trials. 2023; 24: 758.

[35] Dahle GO, Salminen PR, Moen CA, Eliassen F, Jonassen AK, Haaverstad R, et al. Esmolol added in repeated, cold, oxygenated blood cardioplegia improves myocardial function after cardiopulmonary bypass. Journal of Cardiothoracic and Vascular Anesthesia. 2015; 29: 684–693.

[36] Nishina D, Chambers DJ. Efficacy of esmolol cardioplegia during hypothermic ischaemia. European Journal of Cardio—Thoracic Surgery. 2018; 53: 392–399.

[37] Liu X, Shao F, Yang L, Jia Y. A pilot study of perioperative esmolol for myocardial protection during on-pump cardiac surgery. Experimental and Therapeutic Medicine. 2016; 12: 2990–2996.

[38] Francica A, Tonelli F, Rossetti C, Tropea I, Luciani GB, Faggian G, et al. Cardioplegia between evolution and revolution: from depolarized to polarized cardiac arrest in adult cardiac surgery. Journal of Clinical Medicine. 2021; 10: 4485.

[39] Scorsin M, Mebazaa A, Al Attar N, Medini B, Callebert J, Raffoul R, et al. Efficacy of esmolol as a myocardial protective agent during continuous retrograde blood cardioplegia. The Journal of Thoracic and Cardiovascular Surgery. 2003; 125: 1022–1029.

[40] Fujii M, Chambers DJ. Cardioprotection with esmolol cardioplegia: efficacy as a blood-based solution. European Journal of Cardio—Thoracic Surgery. 2013; 43: 619–627.

[41] Zaugg M, Schaub MC, Pasch T, Spahn DR. Modulation of beta-adrenergic receptor subtype activities in perioperative medicine: mechanisms and sites of action. British Journal of Anaesthesia. 2002; 88: 101–123.

[42] Cafaro T, Allwood M, McIntyre WF, Park LJ, Daza J, Ofori SN, et al. Landiolol for the prevention of postoperative atrial fibrillation after cardiac surgery: a systematic review and meta-analysis. Canadian Journal of Anesthesia. 2023; 70: 1828–1838.

[43] Kaminohara J, Hara M, Uehara K, Suruga M, Yunoki K, Takatori M. Intravenous landiolol for the prevention of atrial fibrillation after aortic root, ascending aorta, and aortic arch surgery: a propensity score-matched analysis. JTCVS Open. 2022; 11: 49–58.

[44] Chapalain X, Oilleau JF, Henaff L, Lorillon PharmD P, Saout DL, Kha P, et al. Short acting intravenous beta-blocker as a first line of treatment for atrial fibrillation after cardiac surgery: a prospective observational study. European Heart Journal Supplements. 2022; 24: D34–D42.

[45] Hao J, Zhou J, Xu W, Chen C, Zhang J, Peng H, et al. Beta-blocker landiolol hydrochloride in preventing atrial fibrillation following cardiothoracic surgery: a systematic review and meta-analysis. Annals of Thoracic and Cardiovascular Surgery. 2022; 28: 18–31.

[46] Kowalik K, Silverman M, Oraii A, Conen D, Belley-Côté EP, Healey JS, et al. Landiolol for perioperative atrial tachyarrhythmias in cardiac and thoracic surgery patients: a systematic review and meta-analysis. British Journal of Anaesthesia. 2024; 133: 222–225.

[47] Levy B, Slama M, Lakbar I, Maizel J, Kato H, Leone M, et al. Landiolol for treatment of new-onset atrial fibrillation in critical care: a systematic review. Journal of Clinical Medicine. 2024; 13: 2951.

[48] Floria M, Oancea AF, Morariu PC, Burlacu A, Iov DE, Chiriac CP, et al. An overview of the pharmacokinetics and pharmacodynamics of landiolol (an ultra-short acting β1 selective antagonist) in atrial fibrillation. Pharmaceutics. 2024; 16: 517.